期刊文献+

硫酸长春碱乳酸-羟基醋酸共聚物微球的处方和制备工艺研究 被引量:1

Effects of formulation factors on encapsulation efficiency and release profiles of vinblastine sulfate loaded microspheres
下载PDF
导出
摘要 目的:制备硫酸长春碱生物可降解注射微球,考察处方和制备工艺对微球包封率及释放度的影响。方法:以乳酸-羟基醋酸共聚物(PLGA)为载体材料,分别采用O/O型和W/O/W乳化溶剂挥发法制备微球。结果:采用O/O型乳化溶剂挥发法制备的微球表面光滑无孔洞,内部结构致密;W/O/W型微球表面有较多皱褶,内部结构多孔。采用O/O型乳化溶剂挥发法制备的微球包封率在70%左右,明显高于W/O/W型乳化溶剂挥发法制备的微球,释药速度明显低于第2种方法制备的微球。采用O/O型乳化溶剂挥发法,以PLGA(50∶50.10000)制备的微球在体外可持续释药21d以上。结论:硫酸长春碱PLGA微球的制备工艺可行,缓释特征明显,无突释效应。 OBJECTIVE To study the effects of formulation factors on encapsulation efficiency and drug release profile of vinblastine sulfate loaded mierospheres. METHODS Vinblastine sulfate loaded microsphere was prepared with poly(lactic-co- glycolic acid) (PLGA) by O/O and W/O/W emulsion solvent evaporation method. RESULTS Drug loaded microspheres prepared by O/O emulsion solvent evaporation method showed a relative smooth surface and dense interior structures, while microspheres prepared by the latter method possessed rough surface with very porous interior structures. The encapsulation efficiency and drug release rate of mierospheres prepared by the first method was significant higher and faster than that of the microspheres prepared by the latter method. The microspheres prepared with PLGA(50:50. 10000) could sustain release for 21 days. CONCLUSION The preparation and the formulation of drug loaded microspheres is simple and available. The microspheres showed a good controlled release characteristics without burst release.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第14期1151-1154,共4页 Chinese Journal of Hospital Pharmacy
基金 湖北省自然科学基金项目(编号:2006ABA007)
关键词 硫酸长春碱 乳酸-羟基醋酸共聚物 微球 vinblastine sulfate poly(lactic-co-glycolic acid) microspheres
  • 相关文献

参考文献6

  • 1Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity[J]. J Clin Invest,2000,105(8):1045.
  • 2李珊珊,吴红,吴道澄.载药纳米粒子肿瘤治疗机制的研究进展[J].医学研究生学报,2004,17(7):632-636. 被引量:8
  • 3Iwata M,Nakamura Y, Meginity JW. In vitro and in vivo release properties of brilliant blue and tumor necrosis factor-alpha (TNF-a) from poly(D,L-lactic-co-glycolic acid) multi- phase mierospheres[J]. J Microen, 1999,16(6) :777-792.
  • 4Diaz RV, Llabre ' s ME' vora C. One-month sustained release microsphere of ^125I-bovine calcitonin in vitro-in vivo studies[J]. J Control Release, 1999,59: 55-62.
  • 5Fu XD, Ping QN, Gao YL. Effects of formulation factors on encapsulation efficiency and release behavior in vitro of huperzineA PLOA rnicrospheres[J] . J Microencap , 2005, 22 (1):57-66.
  • 6Yang YY, Chung TS,Ng NP. Morphology,drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction /evaporation method[J]. Biomaterials, 2001, 22: 231-241.

二级参考文献24

  • 1[1]Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function [ J ]. J Control Release,2001,74 ( 1-3 ) :7 -25.
  • 2[2]Damge C,Vranckx H, Balschmidt P et al. Poly( alkyl cyanoacrylate) nanospheres for oral administration of insulin [ J ]. J Pharm Sci, 1997,86(12) :1403-1409.
  • 3[3]Cristiano RJ. Targeted, non-viral gene delivery for cancer gene therpy [ J ]. Front Biosic, 1998,15 ( 3 ): 1161-1170.
  • 4[4]Maeda H, Wu J, Sawa T et al. Tumor vascular permeability and the EPR effect in macrmolecular[ J]. J Control Release , 2000 , 65(1-2) :271-284.
  • 5[5]Esser S, Lampugnani MG, Corada M et al. Vascular endothelial growth factor induces VE-Casdherin tyrosine phosphorylation in endothelial cells[ J]. J Cell Sci, 1998,111 ( Pt13 ): 1853-1865.
  • 6[6]Verdun C, Brasseur F, Vranckx H et al. Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles,Cancer Chemother [ J ]. Pharmacal, 1990,26 ( 1 ): 13-1 8.
  • 7[8]Soma CE, Dubernet C, Couvreur P et al. Investigation of the macrophages on the cytotoxicity of doxorubicin-loaded nanoparticles on M5076 calls in vitro[J]. J Control Relaese,2000,68 (2) :283-289.
  • 8[9]Moghimi SM, Hunter AC, Murray GC. Long-circulating and targetspecific nanoparticles: theory to practice [ J ]. Pharmacol Rev,2001,53(2) :283-318.
  • 9[10]Gulyaev AE, Gelperina SE, Skidan IN et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles[ J]. Pharm Res,1999,16(10) :1564-1569.
  • 10[11]Kreuter J. Nanoparticulate systems for brain delivery of drugs [ J ].Adv Drug Deliv Rev,2001,47( 1 ) :65-81.

共引文献7

同被引文献13

  • 1李珊珊,吴红,吴道澄.载药纳米粒子肿瘤治疗机制的研究进展[J].医学研究生学报,2004,17(7):632-636. 被引量:8
  • 2丁亚芳,包永明,安利佳.长春碱类抗肿瘤药物的研究进展[J].中国医药工业杂志,2005,36(7):424-428. 被引量:29
  • 3王尊元,马臻,沈正荣.聚乳酸的制备及其影响因素的研究[J].齐鲁药事,2006,25(10):619-622. 被引量:2
  • 4Igor VZ, Norbert M, Quet FA, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention [J]. Journal of Controlled Release,2005,104 ( 1 ): 103-111.
  • 5Theresa MA, Pieter RC. Drug Delivery System: Entering the Mainstream [J]. Science. 2004,303(19): 1818-1822.
  • 6Szabolcs M, Philip H, Howard R, et al. Diffusivity and distribution of vinblastine in three-dimensional turnout tissue: Experimental and mathematical modeling [J]. European Journal of Cancer,2006,42 (14): 2404-2413.
  • 7Kristel VC, Dieter H, Leen VA, et al. Vinblastine and doxorubicin administration to pregnant mice affects brain development and behaviour in the offspring [J]. NeuroToxicology,2009,30(4):647-657.
  • 8Klement G, Baruehel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody in-duees sustained tumor regression without overt toxicity [J]. J Clin Invest, 2000, 105 (8): 1045.
  • 9Yogesh P , Tanmoy S, Linan M,et al. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance [J]. Journal of Controlled Release, 2009.136(1):21-29.
  • 10Chen HW, Gao J, Lu Y, et al. Preparation and characterization of PE38KDEL-Ioaded anti-HER2 nanoparticles for targeted cancer therapy [J]. Journal of Controlled Release,2008.128(3):209-216.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部